Could a new drug ease core autism symptoms in adults? phase 2 trial launches
NCT ID NCT06500637
First seen Apr 18, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests whether a drug called TB006 can improve core autism symptoms in adults aged 18-35 with moderate or greater autism severity. About 45 participants will receive either TB006 or a placebo for 14 weeks, with all participants having a chance to receive TB006 later. The goal is to see if TB006 reduces autism severity and improves daily functioning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rossignol Medical Center
RECRUITINGPhoenix, Arizona, 85050, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rossignol Medical Center
RECRUITINGAliso Viejo, California, 92656, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.